Press Releases

Date Title and Summary Additional Formats
Toggle Summary Biocept to Participate in Three Virtual Investment Conferences in March
Company presentation features neuro-oncology program with goal of becoming standard of care for diagnosis, characterization and monitoring of metastatic spread of solid tumors to the central nervous system (CNS) Provides update on COVID-19 testing with more than 300,000 samples received SAN DIEGO
View HTML
Toggle Summary Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO --(BUSINESS WIRE)--Mar. 3, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 38,250 shares of its common stock to six new employees.
View HTML
Toggle Summary Aegea Biotechnologies Announces Supply Agreement with Biocept for New COVID-19 Test with the Ability to Distinguish Virus Strains and Quantify Viral Load
COVID-19 test, based on Aegea’s next-generation COVID-19 assay kit using Switch-Blocker™ technology, may provide answers that support screening and managing patients SAN DIEGO --(BUSINESS WIRE)--Mar. 2, 2021-- Aegea Biotechnologies, Inc. , an innovative life science company with an extensive
View HTML
Toggle Summary Biocept and Protean BioDiagnostics Establish Research Collaboration to Demonstrate Advantages of Biocept’s Target Selector™ Assay Kit for Non-Small Cell Lung Cancer Patients
Target Selector™ EGFR assays offer ultra-high sensitivity and require less tumor sample than most commercial assays SAN DIEGO --(BUSINESS WIRE)--Feb. 23, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, will collaborate with Protean
View HTML
Toggle Summary Study Shows Biocept’s Target Selector™ Detects Mutations in “Quantity Not Sufficient” Specimens in Non-Small Cell Lung Cancer Patients
Data to be presented at Molecular Med Tri-Con Virtual Conference SAN DIEGO --(BUSINESS WIRE)--Feb. 16, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, will present data showing that its Target Selector™ molecular assay kit detects
View HTML
Toggle Summary Biocept Provides Update on COVID-19 Testing with More than 250,000 Samples Received
SAN DIEGO --(BUSINESS WIRE)--Feb. 3, 2021-- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, provides an update on its COVID-19 testing with more than 250,000 samples received to date for processing
View HTML
Toggle Summary Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO --(BUSINESS WIRE)--Feb. 2, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, today announced that it has granted
View HTML
Toggle Summary Biocept Issues Letter to Stockholders
SAN DIEGO --(BUSINESS WIRE)--Jan. 12, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular testing to provide physicians with clinically actionable information to improve patient outcomes, announces that President and CEO Michael W.
View HTML
Toggle Summary Biocept to Present at H.C. Wainwright Virtual BioConnect Conference
CEO Michael Nall to participate in diagnostics and devices panel discussion hosted by former FDA Commissioner Dr. Scott Gottlieb SAN DIEGO , Jan. 4, 2021 /PRNewswire/ --  Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to
View HTML
Toggle Summary Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , Dec. 31, 2020 /PRNewswire/ --   Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, today announced that it has granted
View HTML